|Furiex Pharmaceuticals, Inc.|
3900 Paramount Parkway
United States - Map
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The companys products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.
|Furiex Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Mar 1, 2014 is 4. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 3; Compensation: 5.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. June S. Almenoff M.D., Ph.D., F.A.C.P.,
Pres, Chief Medical Officer and Director
|Dr. Paul S. Covington M.D.,
Sr. VP of Clinical Devel. and Operations
|Dr. Gail F. McIntyre Ph.D., CH (ASCP), DABT,
Sr. VP of Research
|Mr. Sailash Patel ,
Chief Financial Officer and VP of Strategic Devel.
|Dr. Nadine C. Chien Ph.D., Esq.,
VP of Legal Affairs and Sec.
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|